Insider Selling: Zynex, Inc. (NASDAQ:ZYXI) CFO Sells $76,800.00 in Stock

Zynex, Inc. (NASDAQ:ZYXI) CFO Daniel J. Moorhead sold 10,000 shares of Zynex stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $7.68, for a total value of $76,800.00. Following the completion of the sale, the chief financial officer now directly owns 19,738 shares of the company’s stock, valued at approximately $151,587.84. This represents a 33.63 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Zynex Stock Performance

NASDAQ:ZYXI opened at $7.99 on Thursday. The company has a market cap of $254.48 million, a P/E ratio of 53.27 and a beta of 0.54. The firm’s 50 day moving average is $8.09 and its two-hundred day moving average is $8.17. Zynex, Inc. has a fifty-two week low of $7.15 and a fifty-two week high of $13.77. The company has a quick ratio of 3.15, a current ratio of 3.94 and a debt-to-equity ratio of 1.66.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Investment Partners Asset Management Inc. grew its position in Zynex by 10.4% during the fourth quarter. Investment Partners Asset Management Inc. now owns 12,942 shares of the company’s stock valued at $104,000 after acquiring an additional 1,220 shares during the period. JPMorgan Chase & Co. lifted its stake in shares of Zynex by 3.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 40,985 shares of the company’s stock valued at $334,000 after purchasing an additional 1,318 shares in the last quarter. Gladius Capital Management LP grew its holdings in shares of Zynex by 53.4% during the 3rd quarter. Gladius Capital Management LP now owns 5,002 shares of the company’s stock worth $41,000 after purchasing an additional 1,742 shares during the period. Jane Street Group LLC increased its position in Zynex by 8.9% during the 3rd quarter. Jane Street Group LLC now owns 23,530 shares of the company’s stock worth $192,000 after purchasing an additional 1,929 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in Zynex during the 4th quarter worth approximately $26,000. 29.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, HC Wainwright reissued a “buy” rating and issued a $17.00 price target on shares of Zynex in a research note on Friday, December 6th.

Zynex Company Profile

Zynex, Inc, together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device.